MDxHealth disclosed it has received an additional Nasdaq notice of noncompliance related to minimum market value for continued listing. The diagnostics company previously warned that its stock failed the $1 minimum bid price requirement earlier in the month, setting up delisting risk. Nasdaq has given MDxHealth until Jan. 19, 2027 to regain compliance with the $35 million market value requirement for at least 10 consecutive business days, while it has until Dec. 28 for the $1 minimum bid condition. MDxHealth also noted earlier operational moves, including discontinuing one flagship urinary tract infection test and reporting a 13% rise in Q1 revenues.